Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. - Wikidata - wikimedia - TriplyDB

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.

http://www.wikidata.org/entity/Q31049802

about

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema Recent developments in laser treatment of diabetic retinopathy Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema Cost-effectiveness of treatment of diabetic macular edema.Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.Trends in the Care of Diabetic Macular Edema: Analysis of a National Cohort Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice.What the comprehensive economics of blindness and visual impairment can help us understand Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole Anti-VEGF therapy for diabetic macular edema.Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland.Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations?Treatment of diabetic maculopathy.

P2860

Q24202071-A3FC44F6-2D88-4771-B1D0-512C57B3F30D Q28084139-F0E30BF9-F16C-4ACB-80D1-637A5DE45DF2 Q28292764-9AE9753C-A0EB-431C-8F04-A9012EF29F18 Q33606611-FD24A17A-01AF-411C-B814-0527DBFE917B Q34410824-7F3A577E-8980-4FD9-8BB4-EA677F21B133 Q34624487-70680163-9286-45B9-9942-013DC0192F19 Q34711043-D073099B-F670-44CD-9E5A-40FBBA0F749B Q35592307-444C94FB-C72B-43A1-8E63-04EB5BE5F322 Q35933773-D6157323-E377-40D0-8AC9-EC596D4BAFF3 Q36095304-D1C7A3A4-3D30-4EF0-A0C6-DD684362F731 Q36099741-86C368E9-B39D-48E7-B39B-75F8E86D8632 Q36377687-7E1FAAF2-4C7B-44F5-925D-EA29678152E8 Q37037822-A094C60C-42ED-4B5B-B6B4-865A01D6AA08 Q38219571-76F0F372-EE78-4000-A807-7A418A551CF7 Q38376964-ACA3D700-1FED-4983-8BE4-C2DB25F29B1C Q39867113-41676CDE-7107-42DD-91F6-F6F80A50374E Q48221657-4BAFDBB7-685C-439E-B82C-3764637DF069 Q53645110-E8B27CB1-C6AC-4A7A-882E-7F8B1CC52416

P2860

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.

http://www.wikidata.org/entity/Q31049802

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.

@ast

Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.

@en

type

label

Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.

@ast

Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.

@en

prefLabel

Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.

@ast

Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.

@en

P1433

Q31049802-F12CF869-AD72-41AB-B579-D4D850A3EEA1

P1476

Q31049802-77EAF359-4CD6-4959-B472-24EF3CF5E26C

P2093

Q31049802-2FAEC488-C505-462A-A1FB-AF0B4FAF54B4

Q31049802-34FA0CD4-3DA3-42B0-BA94-47BF2DD629B6

Q31049802-7FF80F7F-BBB2-4559-8641-8BFC3C706969

Q31049802-8FE60AD5-F002-4076-B4F6-1502DE1D066C

Q31049802-A9F855F0-E1EC-401B-A58B-60B840F3FA3C

Q31049802-B66E5195-A8B7-445C-8029-DB7C936E1346

Q31049802-F0C47B79-8A1A-4999-A502-1E184F49EE9F

P2860

Q31049802-08FD042E-C4CD-4CFE-8E4D-222452A58601

Q31049802-1509D861-7E0E-4EA1-93AC-C198D7244F56

Q31049802-2163196C-AC21-4917-94EC-DD56A7A90BB2

Q31049802-46A2DAA5-3B2D-4404-95F5-7C6E90059BC6

Q31049802-4CE77735-3E4F-4ED4-8CCE-F78E33AFDC62

Q31049802-5537DD19-0198-4B9A-9FE0-A4BD483CA4CC

Q31049802-798B697F-C197-44BC-9275-4F4E01259196

Q31049802-87B52053-E116-4DCE-8686-9C2B3EBDA4EC

Q31049802-94A7C763-DE2D-4570-B616-ED275A83C0C8

Q31049802-9F2FEDAC-013B-42AA-9982-D9BAE10AD88C

P304

Q31049802-347C6E49-79C6-4760-942B-783757DB5334

P31

Q31049802-6B6A845E-F677-4AD3-AC94-5445FB981E6A

P356

Q31049802-778654C6-DB42-4D7F-AB7F-6AFDA0FC17B8

P407

Q31049802-DC29DC08-EFC9-4DB8-97D8-802C3800155C

P433

Q31049802-7DF81FB1-D88B-46E5-A6AD-AC3D461A8338

P478

Q31049802-9430ED74-0D4B-45AD-826D-36957960419E

P50

Q31049802-2A184441-C7C9-42E3-B959-28DFC0899AF7

P577

Q31049802-74F7680D-A4DC-4546-B1F4-4E4CC8F33BB4

P5875

Q31049802-021C0FB6-17E0-4957-AF77-B14D6E89FDE5

P698

Q31049802-EFDA0D1D-869A-465F-BDAA-25262345130B

P932

Q31049802-650B3FB8-9A9E-4F15-BD6E-1CBAD9267B73

P356

BJOPHTHALMOL-2011-300726

P1433

British Journal of Ophthalmology

P1476

Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.

@en

P2093

Henrietta Onwordi

http://www.w3.org/2001/XMLSchema#string

Kerry Gairy

http://www.w3.org/2001/XMLSchema#string

Lieven Annemans

http://www.w3.org/2001/XMLSchema#string

Martin Knudsen

http://www.w3.org/2001/XMLSchema#string

Meghan Gallagher

http://www.w3.org/2001/XMLSchema#string

Rafiq Hasan

http://www.w3.org/2001/XMLSchema#string

Simu Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Ranibizumab for neovascular age-related macular degeneration

Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis.

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

What is the cost of blindness?

P304

688-693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BJOPHTHALMOL-2011-300726

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221686212

http://www.w3.org/2001/XMLSchema#string

P698

22399690

http://www.w3.org/2001/XMLSchema#string

P932

3329632

http://www.w3.org/2001/XMLSchema#string